Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2017

01-12-2017 | Review Article

Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer

Authors: Alireza Nazari, Hossein Khorramdelazad, Gholamhossein Hassanshahi

Published in: International Journal of Clinical Oncology | Issue 6/2017

Login to get access

Abstract

CXC chemokine ligand 12 (CXCL12) is an important member of the CXC subfamily of chemokines, and has been extensively studied in various human body organs and systems, both in physiological and clinical states. Ligation of CXCL12 to CXCR4 and CXCR7 as its receptors on peripheral immune cells gives rise to pleiotropic activities. CXCL12 itself is a highly effective chemoattractant which conservatively attracts lymphocytes and monocytes, whereas there exists no evidence to show attraction for neutrophils. CXCL12 regulates inflammation, neo-vascularization, metastasis, and tumor growth, phenomena which are all pivotally involved in cancer development and further metastasis. Generation and secretion of CXCL12 by stromal cells facilitate attraction of cancer cells, acting through its cognate receptor, CXCR4, which is expressed by both hematopoietic and non-hematopoietic tumor cells. CXCR4 stimulates tumor progression by different mechanisms and is required for metastatic spread to organs where CXCL12 is expressed, thereby allowing tumor cells to access cellular niches, such as the marrow, which favor tumor cell survival and proliferation. It has also been demonstrated that CXCL12 binds to another seven-transmembrane G-protein receptor or G-protein-coupled receptor, namely CXCR7. These studies indicated critical roles for CXCR4 and CXCR7 mediation of tumor metastasis in several types of cancers, suggesting their contributions as biomarkers of tumor behavior as well as potential therapeutic targets. Furthermore, CXCL12 itself has the capability to stimulate survival and growth of neoplastic cells in a paracrine fashion. CXCL12 is a supportive chemokine for tumor neovascularization via attracting endothelial cells to the tumor microenvironment. It has been suggested that elevated protein and mRNA levels of CXCL12/CXCR4/CXCR7 are associated with human bladder cancer (BC). Taken together, mounting evidence suggests a role for CXCR4, CXCR7, and their ligand CXCL12 during the genesis of BC and its further development. However, a better understanding is still required before exploring CXCL12/CXCR4/CXCR7 targeting in the clinic.
Literature
1.
Khorramdelazad H et al (2016) New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis. J Neuroimmunol 290:70–75PubMedCrossRef
2.
Abedinzadeh M et al (2013) S106 Elevated level of CXC chemokines (CXCL1-9-10-12) in bladder transitional cell carcinoma is not altered by surgery. Eur Urol Suppl 4(12):e1214 (S106)
3.
Abedinzadeh M et al (2014) Elevated level of Cxc Chemokines (cxcl1-9-10-12) in bladder transitional cell carcinoma is not attenuated by surgery. Int J Urol 21:A216
4.
Ferdousie VT et al (2017) Serum CXCL10 and CXCL12 chemokine levels are associated with the severity of coronary artery disease and coronary artery occlusion. Int J Cardiol 233:23–38CrossRef
5.
Zhang Y et al (2016) CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress. Sci Rep 6:37827PubMedPubMedCentralCrossRef
6.
Nagasawa T (2014) CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med 92(5):433–439PubMedCrossRef
7.
Newey SE et al (2014) The hematopoietic chemokine CXCL12 promotes integration of human endothelial colony forming cell–derived cells into immature vessel networks. Stem Cells Dev 23(22):2730–2743PubMedPubMedCentralCrossRef
8.
Mao W et al (2016) CXCL12/CXCR4 axis improves migration of neuroblasts along corpus callosum by stimulating MMP-2 secretion after traumatic brain injury in rats. Neurochem Res 41(6):1315–1322PubMedCrossRef
9.
10.
Antoni S et al (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108PubMedCrossRef
11.
Kirkali Z et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6):4–34PubMedCrossRef
12.
Wu D et al (2013) Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis. Mol Med Rep 7(2):684–688PubMedCrossRef
13.
Heney N (1992) Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin N Am 19(3):429–433
14.
Bellmunt J, Guix M (2010) New agents for bladder cancer. Ann Oncol 21(suppl 7):vii56–vii58PubMed
15.
Sylvester RJ, Oosterlinck W, van der OMeijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171(6):2186–2190PubMedCrossRef
16.
Sengupta S, Blute ML (2006) The management of superficial transitional cell carcinoma of the bladder. Urology 67(3):48–54PubMedCrossRef
17.
Hao M et al (2012) Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem Pharmacol 84(2):204–214PubMedCrossRef
18.
19.
Kalvakolanu DV (2017) Cytokine signaling in cancer: novel players and pathways. Elsevier, Amsterdam
20.
Cimadamore A et al (2017) Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. Future Oncol 13(12):1105–1114PubMedCrossRef
21.
Xia Y et al (2017) Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. BMC Cancer 17(1):70PubMedPubMedCentralCrossRef
22.
Zhang S et al (2008) Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J Exp Clin Cancer Res 27(1):62PubMedPubMedCentralCrossRef
23.
Akishima-Fukasawa Y et al (2009) Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol 132(2):202–210PubMedCrossRef
24.
Retz MM et al (2005) CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer 114(2):182–189PubMedCrossRef
25.
Balabanian K et al (2005) The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280(42):35760–35766PubMedCrossRef
26.
27.
Fredriksson R et al (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63(6):1256–1272PubMedCrossRef
28.
Hupe MC et al (2015) Clinical significance of SDF-1 isoforms in bladder cancer. J Clin Oncol 33(7_suppl):334CrossRef
29.
Gosalbez M et al (2014) Differential expression of SDF-1 isoforms in bladder cancer. J Urol 191(6):1899–1905PubMedCrossRef
30.
Yu L et al (2006) Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 374:174–179PubMedCrossRef
31.
Janowski M (2009) Functional diversity of SDF-1 splicing variants. Cell Adhes Migr 3(3):243–249CrossRef
32.
Baggiolini M, Dewald B, Moser B (1997) Human chemokines: an update. Annu Rev Immunol 15(1):675–705PubMedCrossRef
33.
Shirozu M et al (1995) Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 28(3):495–500PubMedCrossRef
34.
Crump MP et al (1997) Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16(23):6996–7007PubMedPubMedCentralCrossRef
35.
Tashiro K et al (1993) Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 261(5121):600–603PubMedCrossRef
36.
Kucia M et al (2006) The migration of bone marrow-derived non-hematopoietic tissue-committed stem cells is regulated in an SDF-1-, HGF-, and LIF-dependent manner. Arch Immunol Ther Exp (Warsz) 54(2):121–135CrossRef
37.
Curiel TJ et al (2004) Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 64(16):5535–5538PubMedCrossRef
38.
Salcedo R et al (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1α. Am J Pathol 154(4):1125–1135PubMedPubMedCentralCrossRef
39.
Yoshida S et al (1997) Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 17(7):4015–4023PubMedPubMedCentralCrossRef
40.
Kryczek I et al (2005) CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 65(2):465–472PubMed
41.
42.
Lambeir A-M et al (2001) Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 276(32):29839–29845PubMedCrossRef
43.
Delgado MB et al (2001) Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur J Immunol 31(3):699–707PubMedCrossRef
44.
McQuibban GA et al (2001) Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 276(47):43503–43508PubMedCrossRef
45.
Valenzuela-Fernández AN (2002) Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem 277(18):15677–15689PubMedCrossRef
46.
Luker KE, Luker GD (2006) Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 238(1):30–41PubMedCrossRef
47.
Vila-Coro AJ et al (1999) The chemokine SDF-1α triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 13(13):1699–1710PubMed
48.
Loetscher M et al (1994) Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem 269(1):232–237PubMed
49.
Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18(1):217–242PubMedCrossRef
50.
Zou Y-R et al (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393(6685):595PubMedCrossRef
51.
52.
Sainz J, Sata M (2007) CXCR4, a key modulator of vascular progenitor cells. Am Heart Assoc 27:263–265
53.
54.
55.
Bachelerie F et al (2013) Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 66(1):71P–79CrossRef
56.
Moriuchi M et al (1997) Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immunol 159(9):4322–4329PubMed
57.
Moriuchi M et al (1999) USF/c-Myc enhances, while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 entry. J Immunol 162(10):5986–5992PubMed
58.
Busillo JM, Benovic JL (2007) Regulation of CXCR4 signaling. Biochim Biophys Acta 1768(4):952–963PubMedCrossRef
59.
Dewan M et al (2006) Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 60(6):273–276PubMedCrossRef
60.
Ishikawa T et al (2006) CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. Int J Oncol 28(1):61–66PubMed
61.
Onoue T et al (2006) Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int J Oncol 29(5):1133–1138PubMed
62.
Kodama J et al (2007) Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 18(1):70–76PubMedCrossRef
63.
Wu J et al (2014) Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis. Tumor Biol 35(4):3709–3715CrossRef
64.
Han M et al (2014) The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis. Tumor Biol 35(5):4589–4597CrossRef
65.
Lv S et al (2014) The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis. Histopathology 64(5):701–712PubMedCrossRef
66.
Billadeau DD et al (2006) Characterization of the CXCR4 signaling in pancreatic cancer cells. J Gastrointest Cancer 37(4):110–119
67.
De Falco V et al (2007) Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 67(24):11821–11829PubMedCrossRef
68.
Borrello MG et al (2005) Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102(41):14825–14830PubMedPubMedCentralCrossRef
69.
Obermajer N et al (2011) PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71(24):7463–7470PubMedPubMedCentralCrossRef
70.
Hirata H et al (2007) CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 13(17):5056–5062PubMedCrossRef
71.
Gangadhar T, Nandi S, Salgia R (2010) The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther 9(6):409–416PubMedCrossRef
72.
73.
Ping Y-F et al (2007) The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells. J Neurooncol 84(1):21–29PubMedCrossRef
74.
Moosavi SR et al (2013) The SDF-1 3′A genetic variation is correlated with elevated intra-tumor tissue and circulating concentration of CXCL12 in glial tumors. J Mol Neurosci 50(2):298–304PubMedCrossRef
75.
Scala S et al (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11(5):1835–1841PubMedCrossRef
76.
Konoplev S et al (2007) Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 109(6):1152–1156PubMedCrossRef
77.
78.
Phillips RJ et al (2003) The stromal derived factor–1/CXCL12–CXC chemokine receptor 4 biological axis in non–small cell lung cancer metastases. Am J Respir Crit Care Med 167(12):1676–1686PubMedCrossRef
79.
Sierro F et al (2007) Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci USA 104(37):14759–14764PubMedPubMedCentralCrossRef
80.
81.
82.
Graham G et al (2012) The biochemistry and biology of the atypical chemokine receptors. Immunol Lett 145(1):30–38PubMedCrossRef
83.
Burns JM et al (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203(9):2201–2213PubMedPubMedCentralCrossRef
84.
85.
Jones S et al (2006) The orphan G-protein coupled receptor RDC1: evidence for a role in chondrocyte hypertrophy and articular cartilage matrix turnover. Osteoarthr Cartil 14(6):597–608PubMedCrossRef
86.
Raggo C et al (2005) Novel cellular genes essential for transformation of endothelial cells by Kaposi’s sarcoma-associated herpesvirus. Cancer Res 65(12):5084–5095PubMedCrossRef
87.
Martínez A et al (2000) Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic β-cells 1. Endocrinology 141(1):406–411PubMedCrossRef
88.
Tripathi V et al (2009) Differential expression of RDC1/CXCR7 in the human placenta. J Clin Immunol 29(3):379PubMedCrossRef
89.
Miao Z et al (2007) CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 104(40):15735–15740PubMedPubMedCentralCrossRef
90.
Wang J et al (2008) The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 283(7):4283–4294PubMedCrossRef
91.
Boldajipour B et al (2008) Control of chemokine-guided cell migration by ligand sequestration. Cell 132(3):463–473PubMedCrossRef
92.
Dambly-Chaudière C, Cubedo N, Ghysen A (2007) Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev Biol 7(1):23PubMedPubMedCentralCrossRef
93.
Levoye A et al (2009) CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113(24):6085–6093PubMedCrossRef
94.
Hartmann TN et al (2008) A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34 + cells. J Leukoc Biol 84(4):1130–1140PubMedCrossRef
95.
Kalatskaya I et al (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75(5):1240–1247PubMedCrossRef
96.
97.
Rajagopal S et al (2010) β-arrestin-but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc Natl Acad Sci USA 107(2):628–632PubMedCrossRef
98.
Rot A, Von Andrian UH (2004) Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22:891–928PubMedCrossRef
99.
Al-Aoukaty A, Schall T, Maghazachi A (1996) Differential coupling of CC chemokine receptors to multiple heterotrimeric G proteins in human interleukin-2-activated natural killer cells. Blood 87(10):4255–4260PubMed
100.
Boutet A et al (2001) Cellular expression of functional chemokine receptor CCR5 and CXCR4 in human embryonic neurons. Neurosci Lett 311(2):105–108PubMedCrossRef
101.
Würth R et al (2014) CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci 8:144PubMedPubMedCentral
102.
Fernandis AZ et al (2004) Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23(1):157PubMedCrossRef
103.
104.
105.
Zabel BA et al (2009) Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol 183(5):3204–3211PubMedCrossRef
106.
Zlotnik A (2004) Chemokines in neoplastic progression. In: Theresa Vincent (ed) Seminars in cancer biology, vol 14, no 3. Elsevier, Stockholm, Sweden, pp 181–185
107.
108.
109.
Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. In: Theresa Vincent (ed) Seminars in cancer biology, vol 14, no 3. Elsevier, Stockholm, Sweden, pp 171–179
110.
Razis E et al (2012) Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer 12(3):183–193PubMedCrossRef
111.
112.
Zhi Y et al (2012) Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Dig Dis Sci 57(3):650–659PubMedCrossRef
113.
114.
Eisenhardt A et al (2005) Expression analysis and potential functional role of the CXCR4 chemokine receptor in bladder cancer. Eur Urol 47(1):111–117PubMedCrossRef
115.
Salvucci O et al (2002) Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 99(8):2703–2711PubMedCrossRef
116.
Tachibana K et al (1998) The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393(6685):591PubMedCrossRef
117.
Muller A et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50PubMedCrossRef
118.
Shen H-B et al (2013) CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer. Tumor Biol 34(3):1839–1845CrossRef
119.
Batsi O et al (2014) Immunohistochemical evaluation of CXCL12–CXCR4 axis and VEGFR3 expression in primary urothelial cancer and its recurrence. Anticancer Res 34(7):3537–3542PubMed
120.
Gu HQ et al (2017) The role of the SDF-1/CXCR7 axis on the growth and invasion ability of endometrial cancer cells. Arch Gynecol Obstet 295:1–9CrossRef
121.
Yu H, Zhang L, Liu P (2015) CXCR7 signaling induced epithelial–mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas. Tumor Biol 36(3):1679–1683CrossRef
122.
Füreder W et al (2006) Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia. Am J Pathol 168(1):123–130PubMedPubMedCentralCrossRef
123.
Jubb AM et al (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24(2):217–227PubMedCrossRef
124.
125.
Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267(2):226–244PubMedCrossRef
126.
127.
128.
129.
Duda DG et al (2011) CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17(8):2074–2080PubMedPubMedCentralCrossRef
130.
Epstein RJ (2004) The CXCL12–CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 4(11):901–909PubMedCrossRef
131.
132.
Liu Q et al (2014) CXCR4 antagonist AMD3100 mobilizes leukocytes from bone marrow and thymus to blood in mice (HEM2P. 265). J Immunol 192(1 Supplement):50.10
133.
Liu T et al (2016) Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice. Exp Hematol Oncol 5(1):19PubMedPubMedCentralCrossRef
134.
135.
Valdivia-Silva J, Medina-Tamayo J, Garcia-Zepeda EA (2015) Chemokine-derived peptides: novel antimicrobial and antineoplasic agents. Int J Mol Sci 16(6):12958–12985PubMedPubMedCentralCrossRef
136.
137.
Jain RK (2008) Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8(4):309–316PubMedCrossRef
Metadata
Title
Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer
Authors
Alireza Nazari
Hossein Khorramdelazad
Gholamhossein Hassanshahi
Publication date
01-12-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1187-x

Other articles of this Issue 6/2017

International Journal of Clinical Oncology 6/2017 Go to the issue

Acknowledgments

List of reviewers 2016–2017

Original Article

Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution

Letter to the Editor

Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection

Original Article

PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer

Original Article

Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)

Original Article

Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits